What is the 13F Pro Quality Score for DMRA?

13F Pro ranks Damora Therapeutics, Inc. (DMRA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DMRA's current score at https://13fpro.ai/research/DMRA (free sign-up required for the full ranking).

Which hedge funds own the most DMRA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DMRA include FMR, Fairmount Funds Management, Avoro Capital Advisors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/DMRA as soon as new 13F filings post.

Where does 13F Pro source DMRA data?

All Damora Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Damora Therapeutics, Inc. files with the SEC under CIK 1800315. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DMRA in?

Damora Therapeutics, Inc. (DMRA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DMRA research updated on 13F Pro?

DMRA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Damora Therapeutics, Inc.(DMRA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1800315 DMRA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

DMRA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Damora Therapeutics, Inc. (DMRA), a Healthcare sector company. DMRA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Damora Therapeutics, Inc. reports net income of $-27.8M, free cash flow of $-20.6M. Top institutional holders of DMRA by reported 13-F value include FMR, Fairmount Funds Management, Avoro Capital Advisors, based on the most recent SEC filings. DMRA trades on the Nasdaq exchange and files with the SEC under CIK 1800315. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DMRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Damora Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-27.8M

Free Cash Flow

Q1 2026

$-20.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-878.8% YoY

$-209.8MFY 2025

FY22 $-61.6MFY23 $-38.3MFY24 $-21.4MFY25 $-209.8M

Operating Income

-847.3% YoY

$-210.9MFY 2025

FY22 $-61.2MFY23 $-39.9MFY24 $-22.3MFY25 $-210.9M

EPS (Diluted)

+121.5% YoY

$3.98FY 2025

FY22 $-2.43FY23 $-36.08FY24 $-18.53FY25 $3.98

Total Assets

+1420.7% YoY

$260.5MFY 2025

FY22 $73.2MFY23 $38.2MFY24 $17.1MFY25 $260.5M

Op. Cash Flow

+63.9% YoY

$-6.7MFY 2025

FY22 $-42.9MFY23 $-36.9MFY24 $-18.6MFY25 $-6.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-209.8M -878.8%	$-21.4M +44.1%	$-38.3M +37.8%	$-61.6M -19.1%	$-51.8M -48.6%	$-34.8M
Operating Income	$-210.9M -847.3%	$-22.3M +44.2%	$-39.9M +34.8%	$-61.2M -17.2%	$-52.2M -55.3%	$-33.6M
EPS (Diluted)	$3.98 +121.5%	$-18.53 +48.6%	$-36.08 -1384.8%	$-2.43 -18.5%	$-2.05	—
Total Assets	$260.5M +1420.7%	$17.1M -55.2%	$38.2M -47.8%	$73.2M -40.1%	$122.2M -28.8%	$171.6M
Operating Cash Flow	$-6.7M +63.9%	$-18.6M +49.5%	$-36.9M +14.0%	$-42.9M +17.9%	$-52.3M -36.9%	$-38.2M

AI Insight: DMRA Financial Trends

A massive Q4 2025 impairment or write-down drove a $201M net loss, yet a large equity raise pushed book value to $512M by Q1 2026.

• Net losses were relatively contained at $3M–$7M per quarter from Q2 2024 through Q3 2025, then spiked to $201M in Q4 2025.

• Equity collapsed from $24M in Q2 2024 to $8M in Q3 2025, then surged to $240M in Q4 2025 and $512M in Q1 2026, signaling significant capital raises.

• Operating cash flow turned briefly positive at $1M in Q4 2025 but reversed sharply to $-21M in Q1 2026.

⚠ The Q4 2025 $202M operating loss dwarfs all prior quarters — identifying the one-time charge driving this is critical.

⚠ Cash burn accelerated to $21M in Q1 2026 — the steepest single-quarter outflow on record; runway relative to $512M equity warrants monitoring.

⚠ No revenue reported across all eight quarters; continued pre-revenue status means losses are entirely dependent on financing activities.

AI Insight: DMRA Ratio Trends

DMRA's return metrics remain deeply negative across all periods, though Q1 2026 shows the least severe losses on record.

• ROE improved from -156.5% in Q3 2025 to -21.7% in Q1 2026, the least negative reading in the observable period.

• ROA moved from deeply negative levels (-78.2% in Q2 2024) to -20.8% in Q1 2026, suggesting reduced asset-level losses.

• ROIC of -24.1% in Q1 2026 compares favorably to -94.6% in Q2 2024, though capital destruction persists.

⚠ OpMargin and NPM remain entirely absent across all quarters — no revenue base is visible to anchor profitability analysis.

⚠ Q4 2024 and Q3 2025 saw ROE spike to -170.3% and -156.5% respectively, signaling episodic one-off loss events worth monitoring.

⚠ TTM ROIC of -46.7% is materially worse than Q1 2026's -24.1%, suggesting recent improvement may not yet be durable.

Get alerted when DMRA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Damora Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DMRA

FMR LLC
$234.3M9,045,481 sh
Fairmount Funds Management LLC
$225.7M8,713,000 sh
Avoro Capital Advisors LLC
$98.0M3,783,000 sh
VR Adviser, LLC
$93.3M3,603,595 sh
FCPM III SERVICES B.V.
$63.2M2,441,000 sh
RA CAPITAL MANAGEMENT, L.P.
$62.1M2,399,310 sh
VIKING GLOBAL INVESTORS LP
$59.9M2,311,082 sh
Bellevue Group AG
$59.5M2,298,000 sh
Remedium Capital Partners, LLC
$53.0M2,045,473 sh
Commodore Capital LP
$50.2M1,939,000 sh

Fund	Value	Shares
FMR LLC	$234.3M	9,045,481
Fairmount Funds Management LLC	$225.7M	8,713,000
Avoro Capital Advisors LLC	$98.0M	3,783,000
VR Adviser, LLC	$93.3M	3,603,595
FCPM III SERVICES B.V.	$63.2M	2,441,000
RA CAPITAL MANAGEMENT, L.P.	$62.1M	2,399,310
VIKING GLOBAL INVESTORS LP	$59.9M	2,311,082
Bellevue Group AG	$59.5M	2,298,000
Remedium Capital Partners, LLC	$53.0M	2,045,473
Commodore Capital LP	$50.2M	1,939,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DMRA on your watchlist

Track score changes the day Damora Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DMRA a good stock to buy?

13F Pro's AI-powered analysis of Damora Therapeutics, Inc. (DMRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DMRA are available on the DMRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DMRA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DMRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Damora Therapeutics, Inc.'s investment landscape.